PL2696856T3 - Formulacja o kontrolowanym uwalnianiu zawierająca hCG - Google Patents

Formulacja o kontrolowanym uwalnianiu zawierająca hCG

Info

Publication number
PL2696856T3
PL2696856T3 PL12706914T PL12706914T PL2696856T3 PL 2696856 T3 PL2696856 T3 PL 2696856T3 PL 12706914 T PL12706914 T PL 12706914T PL 12706914 T PL12706914 T PL 12706914T PL 2696856 T3 PL2696856 T3 PL 2696856T3
Authority
PL
Poland
Prior art keywords
hcg
controlled
release formulation
formulation
release
Prior art date
Application number
PL12706914T
Other languages
English (en)
Inventor
Kompella Venkata Subrahmanya Prasad
Jay Laxman Soman
Pradeep Ratilal Vavia
Lalitkumar Khimjibhai Vora
Original Assignee
Sanzyme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanzyme Limited filed Critical Sanzyme Limited
Publication of PL2696856T3 publication Critical patent/PL2696856T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12706914T 2011-02-16 2012-02-16 Formulacja o kontrolowanym uwalnianiu zawierająca hCG PL2696856T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2298MU2010 2011-02-16

Publications (1)

Publication Number Publication Date
PL2696856T3 true PL2696856T3 (pl) 2017-03-31

Family

ID=45787245

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12706914T PL2696856T3 (pl) 2011-02-16 2012-02-16 Formulacja o kontrolowanym uwalnianiu zawierająca hCG

Country Status (5)

Country Link
EP (1) EP2696856B8 (pl)
ES (1) ES2600926T3 (pl)
HU (1) HUE030248T2 (pl)
PL (1) PL2696856T3 (pl)
WO (1) WO2012110886A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6712003B2 (ja) 2016-10-28 2020-06-17 スパインセラSpinethera 医薬組成物及びその使用
JP2022504427A (ja) * 2018-10-02 2022-01-13 インノコア テクノロジーズ ホールディング ビー.ブイ. ヒト絨毛性ゴナドトロピン(hCG)の徐放配合物
KR102212717B1 (ko) * 2019-11-08 2021-02-08 환인제약 주식회사 지속 방출을 위한 마이크로스피어 및 이의 제조 방법

Also Published As

Publication number Publication date
WO2012110886A4 (en) 2012-11-01
EP2696856B8 (en) 2016-12-21
ES2600926T3 (es) 2017-02-13
WO2012110886A1 (en) 2012-08-23
HUE030248T2 (en) 2017-04-28
EP2696856B1 (en) 2016-09-14
EP2696856A1 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
HK1203146A1 (en) Antibody formulation
SG2014013650A (en) Organic semiconductor formulation
HK1201735A1 (en) Robust controlled-release formulations
GB201111438D0 (en) Formulation
HK1212224A1 (en) A stabilized pemetrexed formulation
ZA201309221B (en) Formulation
GB201102237D0 (en) Particle formulation
ZA201306000B (en) Stable formulation
EP2796410A4 (en) CLINOPTILOTITE WITH STRONTIUM EXCHANGED
EP2744496A4 (en) FORMULATIONS WITH TAXED RELEASE
PT2701506T (pt) Componente de formulação
ZA201402456B (en) Formulation
GB201121377D0 (en) Formulation component
HK1201685A1 (en) Pazopanib formulation
GB201107039D0 (en) Formulation component
PL2696856T3 (pl) Formulacja o kontrolowanym uwalnianiu zawierająca hCG
EP2783435A4 (en) AMENDED
HUE037814T2 (hu) Formulációs összetevõ
GB201106958D0 (en) Formulation
GB2496656B (en) Film-Forming Formulation
GB201220556D0 (en) Sustained-release formulation
GB201107574D0 (en) Semiconductor structure
GB201104284D0 (en) Formulation
GB201110027D0 (en) Topical formulation
GB201110030D0 (en) Topical formulation